Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
Status:
Recruiting
Trial end date:
2027-01-23
Target enrollment:
Participant gender:
Summary
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1
(PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver
metastasis (CRCLM). Thus, the investigators will conduct a prospective trial to explore the
efficacy and safety of targeted treatment based on ctDNA genotyping combined with
tislelizumab and HAIC as salvage treatment for advanced CRCLM failed from standard systemic
treatment, aiming to provide individualized optimized regimen for microsatellite stable (MSS)
CRCLM in salvage treatment.